Apimeds Pharmaceuticals US, Inc.
APUSStock
$0.66
Market Cap$11.05M
P/E—
Div yield—
Beta1.47
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-105.44%
Price vs S&P 500 (4W)-44.95%
VGM Score16.83
Market Capitalization$11.05M
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
APUSApimeds Pharmaceuticals US, Inc. | — | — | F | $0.66 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based therapy targeting inflammation and pain associated with osteoarthritis and multiple sclerosis. The company's lead candidate is already marketed in South Korea under the brand name Apitoxin for osteoarthritis treatment, providing clinical validation of the therapeutic approach.